Valuation: Valneva SE

Market Cap 404M 461M 375M 345M 650M 44.43B 658M 4.47B 1.75B 21.77B 1.73B 1.69B 75.18B P/E 2026 *
-5.81x
P/E 2027 * 5.61x
Enterprise Value 532M 607M 493M 454M 856M 58.49B 866M 5.89B 2.3B 28.67B 2.28B 2.23B 98.98B EV / Sales 2026 *
3.51x
EV / Sales 2027 * 1.58x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.35%
1 week-3.07%
Current month-4.54%
1 month-6.94%
3 months-17.04%
6 months-49.24%
Current year-42.69%
1 week 2.15
Extreme 2.147
2.2
1 month 2.15
Extreme 2.147
2.35
Current year 2.15
Extreme 2.147
5.05
1 year 2.15
Extreme 2.147
5.14
3 years 1.77
Extreme 1.768
6.85
5 years 1.77
Extreme 1.768
28.02
10 years 1.77
Extreme 1.768
28.02
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 2021-07-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 2023-12-19
Director/Board Member 75 2013-03-06
Chairman 65 2023-12-19
Change 5-day change 1-year change 3-year change Capi.($)
-1.30%-3.07% - - 461M
-2.80%-5.99%-1.51%+12.58% 48.5B
+1.61%-0.91%+377.07%+584.68% 38.97B
+2.61%+3.96%+9.16%+61.36% 35.43B
-1.12%-2.99%+26.84%-11.67% 33.65B
-0.58%-0.69%-0.56%+30.30% 26.58B
+1.37%-3.90% - - 16.82B
+0.71%-0.84%+72.13%+116.76% 15.18B
-0.69%-0.20%+9.15%+13.01% 13.89B
+0.26%-0.80%+19.33%-32.25% 12.76B
Average +0.00%-0.93%+63.95%+96.85% 26.87B
Weighted average by Cap. -0.03%-1.00%+76.91%+122.34%

Financials

2026 *2027 *
Net sales 152M 173M 141M 129M 244M 16.68B 247M 1.68B 657M 8.18B 650M 636M 28.23B 294M 335M 272M 251M 473M 32.31B 479M 3.25B 1.27B 15.83B 1.26B 1.23B 54.67B
Net income -66.01M -75.32M -61.17M -56.3M -106M -7.25B -107M -730M -286M -3.55B -283M -277M -12.27B 70.5M 80.43M 65.32M 60.13M 113M 7.75B 115M 780M 305M 3.8B 302M 295M 13.11B
Net Debt 128M 146M 119M 109M 206M 14.07B 208M 1.42B 554M 6.89B 548M 536M 23.8B 60.02M 68.47M 55.61M 51.18M 96.52M 6.59B 97.68M 664M 260M 3.23B 257M 252M 11.16B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change
26-07-19 2.147 0.00%
26-07-21 €2.152 +0.23%
26-07-20 €2.147 0.00%
26-07-17 €2.147 -2.23%
26-07-16 €2.196 -0.50%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.132EUR
Average target price
5.233EUR
Spread / Average Target
+145.47%

Quarterly revenue - Rate of surprise